Deltagen Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2012. The company's consolidated revenues for the three months ended March 31, 2012 totaled $0.508 million. The revenues in the first quarter of 2012 were attributable to license fees associated with the provision of knockout mice and related phenotypic data pursuant to orders placed by customers under the company's DeltaOne(TM) program. The company's consolidated revenues for the three months ended March 31, 2012 included $0.035 million in revenues of Xenopharm Inc., a wholly owned subsidiary of the company. Consolidated net loss; net losses before provision for income taxes and loss from operations for the three months ended March 31, 2012 were $1.074 million. Excluding Benten Expenses, net income before provision for income taxes for the three months ended March 31, 2012 would have been $0.157 million. Cash flows from operating activities were negative at $694,000.